Logo Gobierno de España Logo Ministerio de ciencia, innovación y universidades

Protegemos tu salud a través de la Ciencia

Capricord

Agencia de Evaluación de Tecnologías Sanitarias

THE JOINT ACTION

APRICORD – European Joint Action on Pricing and Reimbursement

CAPRICORD is a European Joint Action that brings together national authorities responsible for the pricing and reimbursement of medicines to strengthen cooperation, improve transparency, and support evidence based decision making across EU health systems.

 The initiative focuses on addressing uncertainty in clinical evidence, enhancing the involvement of patients and healthcare professionals, and supporting sustainable approaches for medicines with high uncertainty, including orphan medicinal products.                                                                      

What is CAPRICORD?

CAPRICORD (Competent Authorities for Pricing and Reimbursement to coordinate Involvement of clinical experts and patients, to manage uncertainty and the Challenges associated to ORphan medicinal proDucts) is a collaborative European project designed to improve equitable access to medicines by reinforcing cooperation between pricing and reimbursement authorities.
The project is developed under the umbrella of the NCAPR network (National Competent Authorities for Pricing and Reimbursement and Public Healthcare Payers) and contributes directly to the objectives of the EU Pharmaceutical Strategy, promoting coordinated, efficient and transparent approaches to medicine evaluation and funding.                                                                                                                                                            

Objectives

The Joint Action focuses on three core objectives:
  1. Develop an uncertainty adapted pricing system. Creation of tools, methods and processes that help national authorities manage uncertainty in clinical evidence, support evidence generation, and enable more consistent, transparent and patient focused pricing decisions
  2. Improve public and clinical expert engagement. Strengthening the capacity of Member States to involve patients and healthcare professionals in pricing and reimbursement processes through harmonised methods, training materials and shared guidelines.
  3. Address challenges in orphan drug pricing and reimbursement. Developing shared tools, exploring data collection approaches, and assessing opportunities for joint negotiations to support sustainable access to orphan medicines across Europe.

Project Structure

CAPRICORD is organised into seven Work Packages, each led by a national institution with expertise in the relevant area:

  1.  P1 – Coordination
  2. WP2 - Evaluation
  3.  WP3 – Dissemination
  4.  WP4 – Sustainability
  5. WP5 – Uncertainty adapted pricing system
  6. WP6 – Public engagement and transparency
  7. WP7 – Orphan drug pricing and reimbursement challenges

Each Work Package contributes to the overall objectives through specific actions, tools and deliverables.

Consortium & Participating Countries

The project is coordinated by NEAK (Hungary) and involves national competent authorities from across Europe.
Participating countries include:

Hungary, Slovenia, Poland, Spain, Romania, France, Latvia, Cyprus, and Bosnia and Herzegovina, together with associated partners and affiliated entities contributing to specialised areas of work.
Spain participates through the Ministry of Health and the Institute of Health Carlos III (ISCIII), including the Agency for Health Technology Assessment (AETS).                                                                                                                                                        

Funding & Duration

  • Programme: EU4Health (EU4H)
  • Grant Agreement: 101233517
  • Funding body: European Health and Digital Executive Agency (HaDEA)
  • EU Contribution: €1,999,994 (80% of total eligible costs)
  • Project duration: 36 months

CAPRICORD is fully aligned with EU strategies aiming to improve access to affordable, high quality medicines.

Public Deliverables

Publicly available documents, including the project leaflet, methodological outputs and selected reports, will be accessible in this section as they are released.
 

ABOUT NCAPR 

The Network of National Competent Authorities for Pricing and Reimbursement (NCAPR) is a voluntary European collaboration platform that brings together national authorities responsible for the pricing and reimbursement of medicinal products. Its purpose is to strengthen cooperation, promote mutual learning, and support coordinated approaches to ensure timely, equitable and sustainable access to medicines across the EU and EEA.

NCAPR operates as a strategic forum where Member States exchange expertise, identify shared challenges, and discuss policy priorities related to affordability, uncertainty management, transparency, procurement models, and innovative payment mechanisms. While not a legal entity, the network provides an essential space for aligning perspectives and building common positions on high level issues that affect all health systems. Decisions made within NCAPR are not binding and do not replace national competences, but they help shape a coherent European approach to complex pharmaceutical policy questions.

Over recent years, NCAPR has evolved from an ad hoc discussion group into a more structured and continuous form of voluntary cooperation, reflecting the growing need for coordinated responses to rising medicine prices, increasing clinical uncertainty, and financial pressure on national healthcare budgets. The network’s strategic vision is to act as a trusted interlocutor for EU institutions, a reference group for P&R expertise, and a catalyst for advancing shared solutions among Member States.

To operationalise its mission, NCAPR has identified a set of priority areas, including:

  • improving efficiency and affordability to support health system sustainability,
  • strengthening transparency in costing and pricing principles,
  • developing innovative payment, procurement and reimbursement models, and
  • enhancing collaboration among stakeholders across the entire lifecycle of medicinal products.

NCAPR is guided by a Management Group, responsible for governance, strategic planning, and monitoring priority actions. It engages with a wide range of stakeholders, including EU bodies, health technology assessment organisations, patient associations and clinical experts, always ensuring alignment with national responsibilities and European frameworks.

CAPRICORD is fully aligned with NCAPR’s vision and priorities. The Joint Action provides the technical capacity, methods and collaborative tools required to help the network move from experience sharing to practical implementation, supporting Member States as they address affordability, uncertainty and equity in access to m.